| 前收盘价格 | 62.46 |
| 收盘价格 | 62.65 |
| 成交量 | 3,671,065 |
| 平均成交量 (3个月) | 1,855,732 |
| 市值 | 11,723,683,840 |
| 市盈率 (P/E TTM) | 403.87 |
| 预期市盈率 (P/E Forward) | 10.24 |
| 价格/销量 (P/S) | 3.07 |
| 股市价格/股市净资产 (P/B) | 3.48 |
| 52周波幅 | |
| 利润日期 | 28 Apr 2025 - 2 May 2025 |
| 营业毛利率 | 0.77% |
| 营业利益率 (TTM) | 25.34% |
| 稀释每股收益 (EPS TTM) | 0.150 |
| 季度收入增长率 (YOY) | 16.30% |
| 季度盈利增长率 (YOY) | 0.10% |
| 总债务/股东权益 (D/E MRQ) | 1.75% |
| 流动比率 (MRQ) | 1.97 |
| 营业现金流 (OCF TTM) | 335.34 M |
| 杠杆自由现金流 (LFCF TTM) | 619.45 M |
| 资产报酬率 (ROA TTM) | 0.86% |
| 股东权益报酬率 (ROE TTM) | 0.75% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Incyte Corporation | 看涨 | 看涨 |
AIStockmoo 评分
1.0
| 分析师共识 | 3.0 |
| 内部交易活动 | 4.0 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 1.00 |
|
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Core |
| 内部持股比例 | 1.99% |
| 机构持股比例 | 96.77% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Baker Bros. Advisors Lp | 31 Dec 2024 | 30,739,466 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 92.00 (Guggenheim, 51.87%) | 保留 |
| 中 | 74.50 (22.98%) | |
| 低 | 65.00 (Morgan Stanley, 7.30%) | 保留 |
| 平均值 | 77.00 (27.11%) | |
| 总计 | 1 购买, 5 保留 | |
| 平均价格@调整类型 | 63.96 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Morgan Stanley | 24 Mar 2025 | 65.00 (7.30%) | 保留 | 62.78 |
| Guggenheim | 18 Mar 2025 | 92.00 (51.87%) | 保留 | 60.00 |
| Truist Securities | 18 Mar 2025 | 72.00 (18.85%) | 保留 | 60.00 |
| Citigroup | 11 Feb 2025 | 88.00 (45.26%) | 购买 | 66.33 |
| RBC Capital | 11 Feb 2025 | 68.00 (12.25%) | 保留 | 66.33 |
| 23 Jan 2025 | 70.00 (15.55%) | 保留 | 72.53 | |
| Stifel | 10 Feb 2025 | 77.00 (27.10%) | 保留 | 68.30 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 60.55 | - | 974 | 58,976 |
| CLANCY PAUL J | - | - | 0 | 0 |
| FLANNELLY BARRY P | 60.91 | - | 26,135 | 1,591,883 |
| HARRIGAN EDMUND | - | - | 0 | 0 |
| HOPPENOT HERVE | 60.91 | - | 66,899 | 4,074,818 |
| IYENGAR VIJAY K | 60.91 | - | 22,141 | 1,348,608 |
| MORRISSEY MICHAEL JAMES | 60.91 | - | 4,649 | 283,171 |
| STAMOULIS CHRISTIANA | 60.91 | - | 37,568 | 2,288,267 |
| STEIN STEVEN H | 60.91 | - | 58,165 | 3,542,830 |
| SWAIN PAULA J | 60.91 | - | 22,141 | 1,348,608 |
| TROTTA MATTEO | - | 62.08 | -537 | -33,337 |
| 累积净数量 | 238,135 | |||
| 累积净值 ($) | 14,503,824 | |||
| 累积平均购买 ($) | 60.87 | |||
| 累积平均卖出 ($) | 62.08 | |||
| 内部人员交易波幅 ($) | ||||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| HOPPENOT HERVE | 职员 | 01 Apr 2025 | 获得 (+) | 66,899 | 60.91 | 4,074,818 |
| SWAIN PAULA J | 职员 | 01 Apr 2025 | 获得 (+) | 22,141 | 60.91 | 1,348,608 |
| STEIN STEVEN H | 职员 | 01 Apr 2025 | 获得 (+) | 58,165 | 60.91 | 3,542,830 |
| STAMOULIS CHRISTIANA | 职员 | 01 Apr 2025 | 获得 (+) | 37,568 | 60.91 | 2,288,267 |
| MORRISSEY MICHAEL JAMES | 职员 | 01 Apr 2025 | 获得 (+) | 4,649 | 60.91 | 283,171 |
| IYENGAR VIJAY K | 职员 | 01 Apr 2025 | 获得 (+) | 22,141 | 60.91 | 1,348,608 |
| FLANNELLY BARRY P | 职员 | 01 Apr 2025 | 获得 (+) | 26,135 | 60.91 | 1,591,883 |
| HARRIGAN EDMUND | 董事 | 31 Mar 2025 | 363 | - | - | |
| CLANCY PAUL J | 董事 | 31 Mar 2025 | 358 | - | - | |
| BAKER BROS. ADVISORS LP | 董事 | 31 Mar 2025 | 获得 (+) | 974 | 60.55 | 58,976 |
| TROTTA MATTEO | 职员 | 25 Mar 2025 | 处理 (-) | 537 | 62.08 | 33,337 |
| 显示更多 | ||||||
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合